Main Content


Pavlakis E, Neumann M, Merle N, Wieboldt R, Wanzel M, Ponath V, Pogge von Strandmann E, Elmshäuser S, Stiewe T (2023). Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-alpha5-driven metastasis. Journal of Experimental & Clinical Cancer Research 42, 203 [PubMed] [PDF]

Merle N, Elmshäuser S, Strassheimer F, Wanzel M, König AM, Funk J, Neumann M, Kochhan K, Helmprobst F, Pagenstecher A, Nist A, Mernberger M, Schneider A, Braun T, Borggrefe T, Savai R, Timofeev O, Stiewe T (2022). Monitoring autochthonous lung tumors induced by somatic CRISPR gene editing in mice using a secreted luciferase. Molecular Cancer 21, 191. [PubMed] [PDF]

Klimovich B, Meyer L, Merle N, Neumann M, König AM, Ananikidis N, Keber CU, Elmshäuser S, Timofeev O, Stiewe T (2022). Partial p53 reactivation is sufficient to induce cancer regression. Journal of Experimental & Clinical Cancer Research 41, 80. [PubMed] [PDF]

Klimovich B, Merle N, Neumann M, Elmshäuser S, Nist A, Mernberger M, Kazdal D, Stenzinger A, Timofeev O, Stiewe T (2021). p53 partial loss-of-function mutations sensitize to chemotherapy. Oncogene 41, 1011-1023. [PubMed] [PDF]

Gremke N, Polo P, Dort A, Schneikert J, Elmshäuser S, Brehm C, Klingmüller U, Schmitt A, Reinhardt HC, Timofeev O, Wanzel M*, Stiewe T* (2020) mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. Nature Communications 11, 4684. (*equal contribution) [PubMed] [PDF]

Timofeev O, Koch L, Niederau C, Tscherne A, Schneikert J, Klimovich M, Elmshäuser S, Zeitlinger M, Mernberger M, Nist A, Osterburg C, Dötsch V, Mouse Clinic Consortium G, Hrabé de Angelis M, Stiewe T (2020) Phosphorylation control of p53 DNA binding cooperativity balances tumorigenesis and aging. Cancer Research. doi: 10.1158/0008-5472.CAN-20-2002. [PubMed] [PDF]

Kadosh E, Snir-Alkalay I, Venkatachalam A, May S, Lasry A, Elyada E, Zinger A, Shaham M, Vaalani G, Mernberger M, Stiewe T, Pikarsky E, Oren M, Ben-Neriah Y (2020) The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. Nature 586, 133-138. [PubMed] [PDF]

Klimovich B*, Mutlu S*, Schneikert J, Elmshäuser S, Klimovich M, Nist A, Mernberger M, Timofeev O, Stiewe T (2019) Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy. Proceedings of the National Academy of Sciences USA 116, 22288-22293. (*equal contribution) [PubMed] [PDF]

Timofeev O, Klimovich B, Schneikert J, Wanzel M, Pavlakis E, Noll J, Mutlu S, Elmshäuser S, Nist A, Mernberger M, Lamp B, Wenig U, Brobeil A, Gattenlöhner S, Köhler K, Stiewe T (2019) Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses. EMBO Journal: e102096. doi: 10.15252/embj.2019102096. [PubMed] [PDF]

Stiewe T, Haran TE (2018) How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. Drug Resistance Updates 38, 27-43.

Vogiatzi F, Brandt DT, Schneikert J, Fuchs J, Grikscheit K, Wanzel M, Pavlakis E, Charles JP, Timofeev O, Nist A, Mernberger M, Kantelhardt EJ, Siebolts U, Bartel F, Jacob R, Rath A, Moll R, Grosse R, Stiewe T (2016) Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5. Proceedings of the National Academy of Sciences USA 113,  E8433–E8442.[PubMed][PDF]

Wanzel M, Vischedyk JB, Gittler MP, Gremke N, Seiz JR, Hefter M, Noack M, Savai R, Mernberger M, Charles JP, Schneikert J, Bretz AC, Nist A, Stiewe T (2016) CRISPR-Cas9-based target validation for p53-reactivating model compounds Nature Chemical Biology 12, 22–28.[PubMed][PDF]

Bretz AC, Gittler MP, Charles JP, Gremke N, Eckhardt I, Mernberger M, Mandic R, Thomale J, Nist A, Wanzel M, Stiewe T (2016) DeltaNp63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma Nucleic Acids Research 44, 3204–3218.[PubMed][PDF]

Charles JP*, Fuchs J*, Hefter M, Vischedyk JB, Kleint M, Vogiatzi F, Schäfer JA, Nist A, Timofeev O, Wanzel M, Stiewe T (2014) Monitoring the dynamics of clonal tumor evolution in vivo using secreted luciferases. Nature Communications 5, 3981. (*equal contribution)[PubMed][PDF]

Timofeev O, Schlereth K, Wanzel M, Braun A, Nieswandt B, Pagenstecher A, Rosenwald A, Elsässer H-P & Stiewe T (2013) p53 DNA Binding Cooperativity Is Essential for Apoptosis and Tumor Suppression In Vivo. Cell Reports 3: 1512–1526.[PubMed][PDF]

Schlereth K, Heyl C, Krampitz A-M, Mernberger M, Finkernagel F, Scharfe M, Jarek M, Leich E, Rosenwald A & Stiewe T (2013) Characterization of the p53 Cistrome - DNA Binding Cooperativity Dissects p53's Tumor Suppressor Functions. PLoS Genetics 9: e1003726.[PubMed][PDF]

Pribluda A, Elyada E, Wiener Z, Hamza H, Goldstein RE, Biton M, Burstain I, Morgenstern Y, Brachya G, Billauer H, Biton S, Snir-Alkalay I, Vucic D, Schlereth K, Mernberger M, Stiewe T, Oren M, Alitalo K, Pikarsky E & Ben-Neriah Y (2013) A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer Cell 24: 242–256.[PubMed][PDF]

Schlereth K, Beinoraviciute-Kellner R, Zeitlinger MK, Bretz AC, Sauer M, Charles JP, Vogiatzi F, Leich E, Samans B, Eilers M, Kisker C, Rosenwald A & Stiewe T (2010) DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis. Molecular Cell 38: 356–368.[PubMed][PDF]

Beitzinger M, Hofmann L, Oswald C, Beinoraviciute-Kellner R, Sauer M, Griesmann H, Bretz AC, Burek C, Rosenwald A & Stiewe T (2008) p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. EMBO Journal 27: 792–803.[PubMed][PDF]

Schön M, Wienrich BG, Kneitz S, Sennefelder H, Amschler K, Vöhringer V, Weber O, Stiewe T, Ziegelbauer K & Schön MP (2008) KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment. Journal of the National Cancer Institute 100: 862–875.[PubMed][PDF]

Stiewe T (2007) The p53 family in differentiation and tumorigenesis. Nature Reviews Cancer 7: 165–168.[PubMed][PDF]

Cam H, Griesmann H, Beitzinger M, Hofmann L, Beinoraviciute-Kellner R, Sauer M, Hüttinger-Kirchhof N, Oswald C, Friedl P, Gattenlöhner S, Burek C, Rosenwald A & Stiewe T (2006) p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell 10: 281–293.[PubMed][PDF]

Pützer BM, Stiewe T, Rödicker F, Schildgen O, Rühm S, Dirsch O, Fiedler M, Damen U, Tennant B, Scherer C, Graham FL & Roggendorf M (2001) Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes. Journal of the National Cancer Institute 93: 472–479.[PubMed]

Stiewe T & Pützer BM (2000) Role of the p53-homologue p73 in E2F1-induced apoptosis. Nature Genetics 26: 464–469.[PubMed][PDF]